Englander Institute for Precision Medicine
Publications
2022
de Wit R, Powles T, Castellano D, Necchi A, Lee J-L, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN et al..
2022.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.. Br J Clin Pharmacol. 88(7):3182-3192.
Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, Lee JLyun, Fléchon A, Roubaud G, Pouessel D, Zagonel V, Calabrò F et al..
2022.
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. Eur J Cancer. 163:55-65.